Abstract | BACKGROUND: METHODS: All RRMS patients starting fingolimod or ocrelizumab within 6 weeks after natalizumab cessation were included. The primary endpoint was the annualized relapse rate (ARR) at 1 year. RESULTS: We included 54 patients receiving fingolimod and 48 patients receiving ocrelizumab after natalizumab cessation. In multivariate analysis, ARR at 1 year was significantly lower in the ocrelizumab group than in the fingolimod group (0.12 ± 0.39 versus 0.41 ± 0.71, p = 0.026), i.e. a 70.7% lower relapse rate. The cumulative probability of relapses at 1 year was 31.5% (17/54 patients) with fingolimod and 10.4% (5/48 patients) with ocrelizumab, corresponding to a hazard ratio of 3.4 (95% confidence interval: 1.1-11, p = 0.04). CONCLUSIONS:
|
Authors | Kévin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jérôme de Seze |
Journal | Journal of neurology
(J Neurol)
Vol. 269
Issue 6
Pg. 3295-3300
(Jun 2022)
ISSN: 1432-1459 [Electronic] Germany |
PMID | 34982200
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Immunologic Factors
- Immunosuppressive Agents
- Natalizumab
- ocrelizumab
- Fingolimod Hydrochloride
|
Topics |
- Antibodies, Monoclonal, Humanized
- Fingolimod Hydrochloride
(adverse effects)
- Humans
- Immunologic Factors
(adverse effects)
- Immunosuppressive Agents
(adverse effects)
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy)
- Natalizumab
(adverse effects)
- Recurrence
|